Maravai LifeSciences Holdings, Inc. (MAR.F)
| Previous close | 7.15 |
| Open | 7.15 |
| Bid | 6.90 x N/A |
| Ask | 7.15 x N/A |
| Day's range | 6.90 - 7.15 |
| 52-week range | 4.20 - 12.50 |
| Volume | |
| Avg. volume | 17 |
| Market cap | 1.764B |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Steven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc
On June 7, 2024, Steven Cohen (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 6,647,015 shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). This move has increased the firm's stake in Maravai LifeSciences to 5.00% of the total shares outstanding, reflecting a strategic position with a 0.14% portfolio weight and a trade impact of 0.11%. Steven A. Cohen, Chairman and CEO of Point72, a prominent investment advisor, has a distinguished career in the financial markets.
- Zacks
Maravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
- Simply Wall St.
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences Holdings ( NASDAQ:MRVI ) First Quarter 2024 Results Key Financial Results Revenue: US$64.2m (down...
